Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing the substrate-envelope hypothesis with designed pairs of compounds.

ACS chemical biology - 15 Nov 2013

Shen Yang, Altman Michael D, Ali Akbar, Nalam Madhavi N L, Cao Hong, Rana Tariq M, Schiffer Celia A, Tidor Bruce

Abstract excerpt

Acquired resistance to therapeutic agents is a significant barrier to the development of clinically effective treatments for diseases in which evolution occurs on clinical time scales, frequently arising from target mutations. We previously reported a general strategy to design effective inhibitors for rapidly mutating enzyme targets, which we demonstrated for HIV-1 protease inhibition [Altman et al. J. Am. Chem....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computer Simulation
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Protease Inhibitors

Share to Inhibitory Concentration 50

Share to Substrate Specificity

Share to Viral Structural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 23952265
DOI: 10.1021/cb400468c
PMCID: PMC3833293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing the substrate-envelope hypothesis with designed pairs of compounds.PMID 23952265Read ↗

Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.Semantic proximity Read ↗

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.Semantic proximity Read ↗

Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.Semantic proximity Read ↗

Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis.Semantic proximity Read ↗

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.Semantic proximity Read ↗

Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like ProfilesSemantic proximity Read ↗

Combating susceptibility to drug resistance: lessons from HIV-1 protease.Semantic proximity Read ↗

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.Semantic proximity Read ↗

HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistanceSemantic proximity Read ↗

Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease.Semantic proximity Read ↗

Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope.Semantic proximity Read ↗

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.